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Repeated cocaine exposure triggers adaptations in
layer 5/6 glutamatergic neurons in the medial pre-
frontal cortex (mPFC) that promote behavioral
sensitization and drug-seeking behavior. While sup-
pression of metabotropic inhibitory signaling has
been implicated in these behaviors, underlying
mechanisms are unknown. Here, we show that
Girk/KIR3 channels mediate most of the GABAB
receptor (GABABR)-dependent inhibition of layer 5/
6 pyramidal neurons in the mPFC and that repeated
cocaine suppresses this pathway. This adaptation
was selective for GABABR-dependent Girk signaling
in layer 5/6 pyramidal neurons of the prelimbic cor-
tex (PrLC) and involved a D1/5 dopamine receptor-
and phosphorylation-dependent internalization of
GABABR and Girk channels. Persistent suppres-
sion of Girk signaling in layer 5/6 of the dorsal
mPFC enhanced cocaine-induced locomotor activ-
ity and occluded behavioral sensitization. Thus,
the cocaine-induced suppression of GABABR-Girk
signaling in layer 5/6 pyramidal neurons of the
prelimbic cortex appears to represent an early
adaptation critical for promoting addiction-related
behavior.
INTRODUCTION
Drug addiction is marked by subtle yet pervasive disruptions
in cognitive function that facilitate its development and
contribute to a high rate of relapse in addicts, even after
sustained periods of abstinence (Garavan and Hester, 2007).
The prefrontal cortex (PFC) is a critical substrate for many
higher-order cognitive functions, including decision making,
inhibitory behavior, and processing of reward-related informa-
tion (Rushworth et al., 2011). Prolonged exposure to drugs
like cocaine promotes structural, physiological, and functional
abnormalities within the PFC that compromise these functions.For example, activity in areas of the PFC of cocaine addicts is
decreased during withdrawal but increased during intoxication
and exposure to drug-associated cues, the latter of which is
associated with feelings of craving (Goldstein and Volkow,
2011). Lesions of analogous brain regions in the rodent (the
medial PFC, or mPFC) facilitate the acquisition of cocaine
self-administration (Weissenborn et al., 1997), while reversal
of cocaine-induced prefrontal hypoactivity prevents the devel-
opment of compulsive drug-seeking behavior (Chen et al.,
2013).
Glutamatergic pyramidal neurons in the deepest layers of
the mPFC (layers 5 and 6) are the primary output neurons
of the mPFC and represent a major source of excitatory input
to the ventral tegmental area (VTA) and nucleus accumbens
(NAc). Collectively, these structures comprise the ‘‘reward
circuit’’ that mediates response to natural reward and drugs
of abuse (Koob and Volkow, 2010). Frontal corticostriatal
glutamate projections play a critical role in modulating neuro-
transmission in the mesocorticolimbic system (Sesack et al.,
1989; Taber and Fibiger, 1995). Moreover, adaptations in gluta-
mate transmission are produced by repeated exposure to
cocaine that contributes to the expression of addiction-related
behavior. For example, cocaine-induced augmentation of
glutamatergic output to the VTA and NAc is critical for
the development and expression of behavioral sensitization
and reinstatement of drug-seeking behavior (Steketee and
Kalivas, 2011).
Repeated cocaine exposure enhances the responsiveness
of mPFC pyramidal neurons to cocaine and cocaine-related
stimuli (Sun and Rebec, 2006). This phenomenon, and the
related cocaine-induced augmentation of glutamatergic output
from the mPFC to the VTA and NAc, has been linked to adap-
tations in multiple ion conductances in layer 5/6 mPFC pyra-
midal neurons (Dong et al., 2005; Nasif et al., 2005a, 2005b;
Lu et al., 2010). Repeated cocaine also weakens signaling
mediated by inhibitory G protein-coupled receptors, including
the D2 dopamine receptor (D2R) and GABAB receptor
(GABABR), pathways that normally temper the excitability
of mPFC pyramidal neurons (Hearing et al., 2012). Indeed,
decreased D2R- and GABABR-dependent modulation of
glutamatergic output from the mPFC to the VTA and NAc has
been proposed to contribute to the development of cocaineNeuron 80, 159–170, October 2, 2013 ª2013 Elsevier Inc. 159
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Figure 1. GABABR-Dependent Signaling
and Excitability in Layer 5/6 PrLC Pyramidal
Neurons
(A) Depiction of a coronal section containing the
mPFC. The shaded region denotes the area of
the prelimbic cortex (PrLC) targeted for analysis.
Given the lack of definitive anatomic borders,
a small number of neurons in the ventral
cingulate (cg) and dorsal infralimbic (ILC) sub-
regions of the mPFC was likely included in the
analysis.
(B) Outward current (top trace) evoked by bac-
lofen (200 mM) in a wild-type layer 5/6 PrLC
pyramidal neuron (Vhold = 60 mV). The baclofen-
induced current (IBaclofen) was associated with
a decrease in input resistance (RIN, bottom
trace) and was reversed by the GABABR antag-
onist CGP54626 (CGP, 2 mM). Scale bars,
50 pA/5 min.
(C) Concentration-response curve for IBaclofen
in layer 5/6 PrLC pyramidal neurons. Responses
to lower concentrations were normalized to
the current induced by 200 mM baclofen
(Norm. Response %). The EC50 and Hill slope
were 2.1 ± 0.1 mM and 0.54 ± 0.02, respectively
(n = 6).
(D) IBaclofen measured in a wild-type layer 5/6 PrLC
pyramidal neuron in the presence of external Ba2+
(0.3 mM, blue), and in a neuron from a Girk2–/–
mouse (gray). Scale bars, 50 pA/5 min.
(E) IBaclofen in layer 5/6 PrLC pyramidal neurons
from wild-type mice in the presence of external
Ba2+ (0.3 or 1 mM, blue), with (+) or without ()
8Br-cAMP (10 mM) in the pipette solution, as
compared to control (ACSF, black). A significant
effect of group was observed (F(4,43) = 147.8, p <
0.001; n = 4–16/group). ***p < 0.001 versus ACSF;
#p < 0.05 and ##p < 0.01; ^^p < 0.01 versus 0.3 mM
Ba2+ (no 8Br-cAMP).
(F) IBaclofen in layer 5/6 PrLC pyramidal neurons from wild-type (WT),Girk1
–/–,Girk2–/–,Girk2/3–/–, andGirk3–/–mice. A significant effect of genotype was observed
(F(4,54) = 36.2, p < 0.001; n = 9–16/group). ***p < 0.001 versus WT;
##p < 0.01 versus Girk3–/–.
(G) Spiking elicited by current injection (140 pA/1 s) in layer 5/6 PrLC pyramidal neurons from wild-type (top) and Girk2–/– (bottom) mice. Scale, 20 mV, 200 ms.
(H) Current required to evoke an action potential (AP, Threshold) in neurons from Girk2–/– mice, as compared to wild-type (WT) (t(23) = 4.1, p < 0.01; n = 10–14/
group). **p < 0.01 versus WT.
(I) Current-spike plots for wild-type and Girk2–/– layer 5/6 PrLC pyramidal neurons (F(10,223) = 2.4, p < 0.01; n = 9–12/group). *p < 0.05 versus wild-type (within
current injection group).
All data are presented as the mean ± SEM. See Table S1 for electrophysiological properties of layer 5/6 PrLC pyramidal neurons from wild-type andGirk–/–mice,
and Figure S1 for Girk1-4 gene expression analysis in the mPFC and analysis of sEPSC data from wild-type and Girk2–/– mice.
Neuron
Cocaine-Induced Adaptation in GABABR Signalingsensitization (Beyer and Steketee, 2002; Jayaram and Ste-
ketee, 2004).
Themechanisms underlying the cocaine-induced suppression
of metabotropic inhibitory signaling in the mPFC are unresolved.
Reductions in D2R availability and expression have been re-
ported in the PFC of human cocaine addicts and in rats following
cocaine self-administration (Volkow et al., 1993; Briand et al.,
2008). In contrast, no change in expression level of GABABR or
inhibitory (Gi/o) G proteins (Striplin and Kalivas, 1992; Li et al.,
2002), or functional coupling between GABABR and G proteins
(Kushner and Unterwald, 2001), has been observed in the
mPFC following repeated cocaine exposure. Here, we sought
insight into the impact of cocaine on metabotropic inhibitory
signaling in layer 5/6 mPFC pyramidal neurons, focusing on the
postsynaptic GABABR signaling pathway.160 Neuron 80, 159–170, October 2, 2013 ª2013 Elsevier Inc.RESULTS
GABABR-Dependent Inhibition of Layer 5/6 Pyramidal
Neurons of the Prelimbic Cortex
Subregions of the mPFC demonstrate distinct patterns of con-
nectivity and regulate different behavioral functions (Dalley
et al., 2004; Vertes, 2004; Marquis et al., 2007). Increased excit-
atory output from the dorsal mPFC, which includes the interface
between the cingulate (cg) and prelimbic (PrLC) cortices, is
crucial for the expression of sensitization and reinstatement of
drug-seeking behavior (Tzschentke and Schmidt, 2000;
McFarland and Kalivas, 2001; Steketee and Kalivas, 2011;
Chen et al., 2013). Thus, we began by evaluating GABABR-
dependent signaling in layer 5/6 pyramidal neurons in the PrLC
(Figure 1A).
Neuron
Cocaine-Induced Adaptation in GABABR SignalingBath application of a saturating dose of the GABABR agonist
baclofen (200 mM) evoked a robust outward current (IBaclofen)
that showed little desensitization after 10 min of continuous
drug application but was reversed by the GABABR antagonist
CGP54626 (Figure 1B). IBaclofen was dose dependent, with an
EC50 of 2.1 ± 0.1 mM (Figure 1C). IBaclofen was correlated with a
decrease in input resistance and it reversed polarity at 88 ±
2 mV (n = 11), consistent with the activation of a K+ channel.
Indeed, IBaclofen was suppressed by low concentrations of
external Ba2+ (0.3–1 mM) (Figures 1D and 1E), pointing to the
involvement of an inwardly rectifying K+ channel.
GABABRs activate G protein-gated inwardly rectifying K
+
(Girk/KIR3) channels in many neurons, including layer 2/3
mPFC pyramidal cells (Wang et al., 2010). To test whether Girk
channels mediate the GABABR-dependent inhibition of layer
5/6 PrLC pyramidal neurons, we next compared IBaclofen in slices
fromwild-type andGirk–/–mice. WhileGirk ablation had no effect
on many parameters of layer 5/6 PrLC pyramidal neurons (Table
S1 available online), IBaclofen was 60% smaller in neurons from
Girk–/– mice, with the smallest currents seen in slices from
Girk1–/– and Girk2–/– mice (Figures 1D and 1F). These findings
were consistent with RT-PCR data from micropunches contain-
ing the mPFC, which showed expression of Girk1, Girk2, and
Girk3 in this brain region (Figure S1A).
Girk1 cannot form functional homomeric Girk channels due to
lack of an ER export signal (Ma et al., 2002). Thus, to better
understand the residual IBaclofen measured in Girk
–/– mice, we
evaluated layer 5/6 PrLC pyramidal neurons in slices from
Girk2/3–/– mice. IBaclofen in neurons from Girk2/3
–/– mice was
comparable to that measured in slices from Girk1–/– and
Girk2–/– mice (Figure 1F), arguing that compensatory upregula-
tion of Girk3 is not responsible for the residual current. We next
asked whether upregulation of Girk4 could explain the residual
current measured in slices fromGirk1–/– andGirk2–/–mice. While
sparse Girk4 expression was detected in the deepest layers of
the most posterior aspect of the mPFC (Figure S1B), these rare
neurons were located outside the region targeted for analysis.
Moreover, no difference in Girk4 mRNA levels was observed
in mPFC micropunches from wild-type and Girk2/3–/– mice (Fig-
ure S1C). Thus, the residual IBaclofen seen inGirk
–/– mice appears
to be Girk independent.
The amplitude of the fraction of IBaclofen resistant to Ba
2+
(0.3 mM) was not significantly different in neurons from wild-
type (70 ± 5 pA, n = 10) and Girk2–/– (53 ± 13 pA, n = 6) mice,
nor was it different from the residual current in neurons from
Girk2–/– mice measured in the absence of Ba2+ (79 ± 8 pA;
F(2,25) = 1.98, p = 0.16, n = 12). These findings argue that consti-
tutive Girk ablation did not cause significant alterations in the
Girk-independent component of IBaclofen in layer 5/6 PrLC pyra-
midal neurons. Importantly, the Girk-independent component
of IBaclofen was significantly lower when 8Br-cAMP was included
in the pipette solution (Figure 1E), arguing that this component of
IBaclofen is mediated by a cAMP-dependent current.
Girk Channels and the Excitability of Layer 5/6 PrLC
Pyramidal Neurons
Having established that Girk channelsmediate themajority of the
direct GABABR-dependent inhibition of layer 5/6 PrLC pyramidalneurons, we next investigated the contribution of Girk channels
to the excitability of these neurons. Neurons from Girk2–/– mice
exhibited a reduced threshold for spiking induced by current
injection and an overall leftward shift in the current-spike rela-
tionship (Figures 1G–1I). Previous work has shown that Girk2
ablation can enhance excitatory neurotransmission in neurons
within the VTA and NAc (Arora et al., 2010). To address the
possibility that Girk ablation may enhance excitatory neuro-
transmission in layer 5/6 PrLC pyramidal neurons, we measured
spontaneous EPSCs (sEPSCs) in slices from wild-type and
Girk2–/– mice (Figures S1D and S1E). sEPSCs were readily
observed in slices from wild-type mice with amplitudes and
frequencies consistent with previous report (Wang and Zheng,
2001). sEPSC frequency, but not amplitude, was elevated signif-
icantly in slices from Girk2–/– mice. Collectively, these data sug-
gest that loss of Girk-dependent signaling leads to enhanced
excitability of layer 5/6 PrLC pyramidal neurons.
Cocaine Effects on Layer 5/6 PrLC Pyramidal Neurons
We next asked whether repeated cocaine exposure altered
GABABR-dependent signaling and/or excitability of layer 5/6
PrLC pyramidal neurons (Figure 2). Mice were subjected to a
5-day cocaine dosing regimen that induced behavioral sensitiza-
tion (Figures 2A and 2B). IBaclofen measured 1–2 days after the
last injection was50% smaller in layer 5/6 PrLC pyramidal neu-
rons from cocaine-treated mice as compared to saline controls
(Figures 2C and 2D). The cocaine-induced suppression of
GABABR-dependent signaling correlated with a significant
depolarizing shift in resting membrane potential (saline: 68 ±
2 mV, n = 9; cocaine: 62 ± 1 mV, n = 11; t(18) = 2.9, p <
0.01) and enhanced excitability of layer 5/6 PrLC pyramidal neu-
rons (Figures 2E and 2F). In contrast, a single cocaine injection
had no effect on IBaclofen (Figure 2D) or excitability (data not
shown) of these neurons. The effects of cocaine on GABABR
signaling and excitability of layer 5/6 PrLC pyramidal neurons
were surprisingly durable, persisting for up to 6 weeks after the
last cocaine injection (Figures 2G–2I). In contrast, cocaine-
induced effects on sEPSCs frequencies and amplitude were
time dependent, with enhanced frequencies observed during
early withdrawal and enhanced amplitudes observed after
longer withdrawal periods (Figure S2A–S2D).
Anatomic and Molecular Specificity of the Cocaine-
Induced Adaptation in PrLC Neurons
To examine the anatomic specificity of the cocaine-induced
adaptations in GABABR-dependent signaling and excitability of
layer 5/6 PrLC pyramidal neurons, we measured IBaclofen in layer
5/6 pyramidal neurons of the infralimbic (ILC) cortex, layer 2/3
pyramidal neurons in the PrLC, and layer 5/6 pyramidal neurons
in primary and secondary motor cortices (M1/M2). Importantly,
IBaclofen and excitability measures were unaltered by repeated
cocaine exposure in these cortical pyramidal neurons (Figures
S3A–S3C).
a2-adrenergic receptors (a2-AR) and D2/3 dopamine receptors
(D2/3R) are expressed in PFC pyramidal neurons (Vincent et al.,
1993; Aoki et al., 1998). Thus, we asked whether repeated
cocaine suppressed the direct inhibitory effects of these
receptor systems on layer 5/6 PrLC pyramidal neurons. BathNeuron 80, 159–170, October 2, 2013 ª2013 Elsevier Inc. 161
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Figure 2. Cocaine-Induced Adaptations in
Layer 5/6 PrLC Pyramidal Neurons
(A) Left: the repeated cocaine treatment study
included 2 acclimation days (H, sal), 5 days of
saline or cocaine (15 mg/kg i.p.) injection, and
three time frames (1–2 days, 10–12 days, or 28–
40 days after the final injection) for electrophysio-
logical analysis. Right: depiction of a coronal slice
containing the mPFC. PrLC, prelimbic cortex; ILC,
infralimbic cortex; cg, cingulate cortex.
(B) Distance traveled (m) after saline (sal) injection
on the second acclimation day and after the first
and fifth injections by saline- and cocaine-treated
mice (F(2,109) = 37.1, p < 0.001; n = 9–10/group).
***p < 0.001 versus saline-treated mice (within
day); ##p < 0.01.
(C) IBaclofen in layer 5/6 PrLC pyramidal neurons
frommice given repeated saline (black) or cocaine
(gray), measured 1–2 days after the last injection.
Scale bars, 50 pA/5 min.
(D) IBaclofen in layer 5/6 PrLC pyramidal neurons
measured 1–2 days after a single injection of
cocaine (coc) or saline (sal) or after completing the
repeated dosing regimen. While a single cocaine
injection was without effect on IBaclofen (t(14) =1.3,
p = 0.23; n = 8/group), repeated cocaine treatment
suppressed IBaclofen by 50% (t(18) = 4.6, p <
0.001). ***p < 0.001 versus sal.
(E) AP threshold in layer 5/6 PrLC pyramidal neu-
rons, measured 1–2 days after the last injection of
saline or cocaine. Repeated cocaine suppressed
the AP threshold by35% (t(24) = 2.4, p < 0.05; n =
12–14/group). A single cocaine injection was
without effect on AP threshold (t(14) = 1.5, p = 0.17;
n = 5–10/group; data not shown).
(F) Current-spike plots for layer 5/6 PrLC pyramidal
neurons from repeated saline- and cocaine-
treated mice, measured 1–2 days after the final
injection (F(8,224) = 5.3; p < 0.05; n = 12–14/group).
*p < 0.05 and **p < 0.01, versus sal (within current injection group). Current-spike data were not significantly different in animals treated with a single cocaine or
saline injection (F(8,134) = 1.9; p = 0.07; n = 5–10/group; data not shown).
(G) IBaclofen in layer 5/6 PrLC pyramidal neurons in saline- and cocaine-treated mice, measured 10–12 days (t(30) = 4.6, p < 0.001; n = 14–18/group) or 28–40 days
(t(29) = 3.2, p = 0.004; n = 11–20/group) following the final injection. **p < 0.01 and ***p < 0.001, versus sal.
(H) AP threshold in layer 5/6 PrLC pyramidal neurons from repeated saline- and cocaine-treated mice, measured 10–12 days (t(34) = 4.8, p < 0.001; n = 15–21/
group) or 28–40 days (t(38) = 4.8, p = < 0.001; n = 17–23/group) after the last injection. ***p < 0.001 versus sal.
(I) Current-spike plots for layer 5/6 PrLC pyramidal neurons from saline- and cocaine-treated mice, measured 10–12 days (F(8,311) = 1.1; p < 0.001; n = 15–17/
group) or 28–40 days (F(11,421) = 4.9; p < 0.001; n = 17–23/group) after the final injection **p < 0.01 and ***p < 0.001, versus sal (within current injection group).
All data are presented as the mean ± SEM. See Figure S2 for sEPSC analysis in layer 5/6 PrLC neurons from saline- and cocaine-treated mice.
Neuron
Cocaine-Induced Adaptation in GABABR Signalingapplication of the a2-AR and D2/3R agonists guanfacine (20 mM)
and quinpirole (20 mM), respectively, evoked small (<50 pA)
and transient outward currents in 60% of layer 5/6 PrLC pyrami-
dal neurons (data not shown); no significant differences in cur-
rent amplitudes were seen between slices from cocaine- and
saline-treated animals (Figures S3D and S3E).
Increased glutamatergic transmission arising from the mPFC
to the VTA and NAc is a hallmark of cocaine-induced sensitiza-
tion (Steketee and Kalivas, 2011). To determine whether the
cocaine-induced suppression of GABABR-dependent signaling
and enhanced excitability occurred in layer 5/6 PrLC pyramidal
neurons projecting to the VTA and/or NAc, we used a retrograde
labeling approach. Infusions made into the ventral midbrain
targeted the VTA but also reached areas such as the parabra-
chial pigmented nucleus, paranigral nucleus, and interfasicular162 Neuron 80, 159–170, October 2, 2013 ª2013 Elsevier Inc.nucleus (Figures 3A and 3B). Consistent with past studies (Gab-
bott et al., 2005), Retrobeads injected into the ventral midbrain
primarily labeled populations of neurons in layers 5/6 of the
PrLC and ILC, with some additional labeling in layer 2/3 and
the cingulate region (Figure 3B). Infusions made into the NAc
targeted primarily the core subregion of the accumbens, as it
receives input primarily from the PrLC (Brog et al., 1993) (Figures
3C and 3D). While injections into the NAc labeled some layer 2/3
neurons, most of labeled neurons were found in layers 5/6 of the
PrLC and ILC (Figure 3D).
While Retrobead uptake did not alter IBaclofen (Figure 3F) or
excitability of layer 5/6 PrLC pyramidal cells (data not shown),
IBaclofen was notably larger in the retrograde labeling experi-
ments, a distinction attributable to the older age of the mice
required for these studies (Figure 3F). More importantly,
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Figure 3. Cocaine Adaptations in Layer 5/6
PrLC Pyramidal Neurons Projecting to the
Ventral Midbrain and NAc
(A) Retrobead injection sites in the ventral midbrain
(VM); the respective tracer areas of the individual
experiments in each target region are marked with
different colors.
(B) Representative Retrobead injection site in the
ventral midbrain (VM) in a 50 mm coronal section
counterstained with green Nissl (left). While in-
jections centered on the VTA, neighboring areas
including the parabrachial pigmented nucleus
(PBP), paranigral nucleus (PN), and interfasicular
nucleus (IF) were unavoidably targeted. Corre-
sponding labeling in the PrLC (right; scale bar,
250 mm), with numbers showing approximate
locations of cortical layers. fr, fasciculus retro-
flexus; SN, substantia nigra; MM, medial mammi-
lary nucleus.
(C) Retrobead injection sites in the NAc; the
respective tracer areas of the individual experi-
ments in each target region are marked with
different colors.
(D) Retrobead injection site in the NAc in a 50 mm
coronal section counterstained with green Nissl
(left). While injections were centered on the NAc
core, some labeling of the NAc shell was evident.
Corresponding labeling in the PrLC (right; scale
bar, 250 mm), with numbers showing approximate
locations of cortical layers. ac, anterior commi-
sure; CPu, caudate-putamen; fmi, forceps minor
of the corpus callosum; LV, lateral ventricle.
(E) Retrobead-labeled layer 5/6 mPFC pyramidal
neurons in an acutely isolated brain slice, as
visualized via infrared microscopy (left) and epi-
fluorescence (scale bar, 25 mm). The dashed circle
highlights the cell targeted for evaluation (note the
pipette visible in the left).
(F) Summary of IBaclofen in layer 5/6 PrLC pyramidal
neurons, measured 1–2 days after the last injec-
tion. IBaclofen did not differ in Retrobead-positive
(Rb+) and negative (Rb) layer 5/6 PrLC pyramidal
neurons from saline-treated mice (left, t(6) =1.0, p = 0.4; n = 3–5/group). Cocaine treatment suppressed IBaclofen in layer 5/6 PrLC pyramidal neurons that project
to the ventral midbrain (VM, t(20) = 3.9, p < 0.001; n = 10–12/group) and NAc (t(9) = 5.6, p < 0.001; n = 5–6/group). ***p < 0.001 versus sal.
(G) AP threshold in layer 5/6 PrLC pyramidal neurons projecting to the VM (t(20) = 2.6, p < 0.05; n = 11/group) and NAc (t(13) = 2.3, p < 0.05; n = 6-9/group) in saline-
and cocaine-treated mice *p < 0.05 versus sal.
(H) Current-spike plots for layer 5/6 PrLC pyramidal neurons projecting to the VM in saline- and cocaine-treated mice (F(13,257) = 4.6, p < 0.001; n = 9–10/group).
**p < 0.01 versus sal (within current injection group).
(I) Current-spike plots for layer 5/6 PrLC pyramidal neurons projecting to the NAc in saline- and cocaine-treatedmice (F(13,209) = 2.8; p < 0.05; n = 6–9/group). **p <
0.01 versus sal (within current injection group).
All data are presented as the mean ± SEM. See Figure S3 for data relating to the anatomic and molecular specificity of the cocaine-induced suppression
of IBaclofen.
Neuron
Cocaine-Induced Adaptation in GABABR Signalingrepeated cocaine significantly reduced IBaclofen in, and
augmented the excitability of, layer 5/6 PrLC pyramidal neurons
that project to the medial portions (including the VTA) of
the ventral midbrain (Figures 3F–3H) and NAc (Figures 3F, 3G,
and 3I).
Mechanisms Underlying the Cocaine-Induced
Adaptation in PrLC Pyramidal Neurons
Systemic cocaine administration increases DA levels in the PFC,
exerting both direct and indirect effects on the output of layer 5/6
mPFC pyramidal neurons through activation of D1- and D2-like
receptors in both pyramidal and nonpyramidal cells (Seamansand Yang, 2004; Hyman et al., 2006). To test whether DA recep-
tor activation mediates the repeated cocaine-induced adapta-
tions in layer 5/6 PrLC pyramidal neurons, we pretreated mice
with the D2/3R antagonist sulpiride or the D1/5R antagonist
SCH23390 prior to each cocaine injection (Figure 4). Sulpiride
pretreatment had no effect on the cocaine-induced suppression
of IBaclofen or on the excitability of layer 5/6 PrLC pyramidal neu-
rons. In contrast, SCH23390 pretreatment prevented both the
cocaine-induced suppression of IBaclofen and enhanced excit-
ability, indicating that D1/5R activation is required for the
repeated cocaine-induced suppression of IBaclofen and increased
excitability of layer 5/6 PrLC pyramidal neurons.Neuron 80, 159–170, October 2, 2013 ª2013 Elsevier Inc. 163
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Figure 4. Dopamine Signaling and the Cocaine-Induced Adapta-
tions in Layer 5/6 PrLC Pyramidal Neurons
(A) IBaclofen in layer 5/6 PrLC pyramidal neurons in mice given repeated saline
(sal) or cocaine (coc) injections (noted above the histogram), with daily
pretreatments (noted below the histogram) of saline (black), SCH23390
(0.2 mg/kg, i.p, blue), or sulpiride (50 mg/kg i.p., red). IBaclofen was measured
1–2 days after the final drug treatment (F(3,31) = 6.4, p < 0.01; n = 5–10/group).
**p < 0.01 versus sal/sal.
(B) AP threshold in layer 5/6 PrLC pyramidal neurons from sal/sal-, sal/coc-,
SCH/coc-, and sulp/coc-treated mice (F(3,42) = 5.8, p < 0.01; n = 6–14/group).
**p < 0.01 versus sal/sal; #p < 0.05 versus SCH/coc.
(C) Current-spike plots for layer 5/6 PrLC pyramidal cells from sal/sal-, sal/coc-,
SCH/coc-, and sulp/coc-treated mice (F(24,347) = 2.6, p < 0.001). **p < 0.01 sal/
cocandsulp/cocversussal/sal; #p<0.05sal/cocandsulp/cocversusSCH/coc.
All data are presented as the mean ± SEM.
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Figure 5. Subcellular Trafficking and the Cocaine-Induced Suppres-
sion of IBaclofen
(A) IBaclofen measured in the presence of 0.3 mM extracellular Ba
2+ in layer 5/6
PrLC pyramidal neurons from repeated saline- and cocaine-treated wild-type
mice (t(8) = 0.75, p = 0.48).
(B) Girk2 and GABABR1 (BR1) mRNA levels in mPFC tissue from repeated
saline- (black) and cocaine- (gray) treated mice (n = 4/group), measured by
qRT-PCR 1 day after the final injection (Girk2: t(6) = 0.16, p = 0.9; GABABR1:
t(6) = 0.91, p = 0.4).
(C) Top: representative subsections of immunoblots showing Girk2 (left) and
GABABR1 (BR1) (right) protein levels in tissue punches of the mPFC from
repeated saline- and cocaine-treated mice, 1 day after the final injection.
Bottom: quantification of Girk2 (t(6) = 0.91, p = 0.4) and GABABR1 (t(6) =
0.13, p = 0.8) protein levels, with normalization to the levels of b-actin (n = 4/
group).
(D) Plasma membrane-associated immunogold particle density for Girk2 and
GABABR1 (BR1) in layer 5/6 PrLC pyramidal neuron spines (left, Girk2: t(118) =
4.4, p < 0.001; GABABR1: t(118) = 4.5, p < 0.001; n = 60/group) and dendrites
(right, Girk2: t(118) = 4.6, p < 0.001; GABABR1: t = 4.4, p < 0.001; n = 60/group)
fromsaline- andcocaine-treatedmice (n=6/group). ***p<0.001cocversus sal.
(E) Distribution of Girk2 immunogold particles at the plasma membrane (PM)
and intracellular (intra) sites, expressed as a percentage of total particles
analyzed in spines and dendrites of layer 5/6 PrLC pyramidal neurons from
saline- and cocaine-treated mice (n = 420–430 total particles/group). The
redistribution of GABABR1 was comparable to that seen for Girk2 (data not
shown). **p < 0.01 intra-sal versus PM-sal; ##p < 0.01 intra-coc versus PM-coc.
All data are presented as the mean ± SEM. See Figure S4 for immunoelectron
micrographs from which data in (D) and (E) were extracted.
Neuron
Cocaine-Induced Adaptation in GABABR SignalingWhile repeated noncontingent cocaine administration
weakens the GABABR-dependent modulation of excitatory
output from themPFC (JayaramandSteketee, 2005), nochanges
in the functional coupling between GABABR and G proteins or in
the levels of GABABR or G protein have been reported (Nestler
et al., 1990; Striplin and Kalivas, 1992; Kushner and Unterwald,
2001; Li et al., 2002). To determine whether the cocaine-induced
adaptation in GABABR-dependent signaling is linked to an adap-
tation in downstream effector(s), we measured IBaclofen in the
presence of 0.3 mM Ba2+ in layer 5/6 PrLC pyramidal neurons
from saline- and cocaine-treated wild-type mice. The Ba2+-
insensitive component of IBaclofen was not significantly different
between these groups (Figure 5A), indicating that the cocaine-
induced suppression of GABABR-dependent signaling is
mediated by a selective suppression of the Girk-dependent
component of IBaclofen. Nevertheless, no differences in Girk2
or GABABR1 subunit mRNA levels (Figure 5B), or Girk2 or
GABABR1 total protein levels (Figure 5C), were observed in
mPFC micropunches from cocaine- and saline-treated mice.
To test whether the cocaine-induced suppression of IBaclofen
reflected an internalization of Girk channels, we used quantita-
tive immunoelectron microscopy to compare the subcellular dis-
tributions of Girk2 and GABABR1 in layer 5/6 PrLC pyramidal164 Neuron 80, 159–170, October 2, 2013 ª2013 Elsevier Inc.neurons of cocaine-and saline-treated mice. Consistent with
the quantitative immunoblotting data, there was no obvious dif-
ference in total Girk2 or GABABR1 immunolabeling in layer 5/6
PrLC pyramidal neurons from cocaine-treated and saline-
treated mice. In samples from saline-treated controls, Girk2
and GABABR1 immunoparticles were found mainly in the extra-
synaptic plasma membrane of dendritic shafts and spines, with
35% of immunolabeling observed at intracellular sites (Figures
5D and 5E; Figure S4). In samples from cocaine-treated mice,
the density of Girk2 and GABABR1 immunolabeling in dendritic
and spine membranes was significantly reduced, with a corre-
sponding increase in intracellular labeling (Figures 5D and 5E).
Thus, repeated cocaine treatment triggered a redistribution of
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Figure 6. Reversal of Cocaine-Induced
Adaptations in Layer 5/6 PrLC Pyramidal
Neurons
(A) Top: representative immunoblots examining
levels of phosphorylated Girk2(Ser-9) (pSer9, left)
and GABABR2(Ser-783) (pSer783, right) in mPFC
micropunches from repeated saline and cocaine-
treated mice, measured 1–2 days after the final
injection. Bottom: quantification of Girk2(pSer-9)
(t(6) = 0.85, p = 0.43; n = 4/group) and
GABABR2(pSer-783) (t(10) = 3.9, p = 0.003; n = 6/
group) with normalization to the total level of Girk2
and GABABR2 (BR2), respectively. **p < 0.01
versus sal.
(B) Representative IBaclofen traces in layer 5/6 PrLC
pyramidal neurons from repeated saline- (red)
and cocaine-treated (blue) mice, measured with
100 nM okadaic acid (OA) in the pipette solution,
next to a control recording in a neuron from a
repeated cocaine-treated mouse measured in the
absence of OA (gray). Scale bars, 50 pA/5 min.
(C) IBaclofen measured in layer 5/6 PrLC pyramidal neurons from saline- and cocaine-treated mice, in the absence or presence of OA (F(3,21) = 10.22, p < 0.001).
**p < 0.01 versus sal (no OA); ##p < 0.01 versus coc/OA.
(D) AP threshold in layer 5/6 PrLC pyramidal neurons from saline- and cocaine-treatedmice, measuredwith andwithout OA in the pipette solution (F(3,25) = 7.2, p <
0.002; n = 6–8/group). **p < 0.01 versus versus sal (no OA); ###p < 0.001 versus coc/OA.
(E) Current-spike plots for layer 5/6 PrLC pyramidal neurons from saline- and cocaine-treated mice, measured with and without OA in the pipette solution
(F(24,224) = 4.7, p < 0.001; n = 6-8/group). *p < 0.05, **p < 0.01, ***p < 0.001, versus sal and coc/OA.
All data are presented as the mean ± SEM.
Neuron
Cocaine-Induced Adaptation in GABABR SignalingGirk2 andGABABR1 from the dendritic membrane to intracellular
sites in layer 5/6 PrLC pyramidal neurons.
Surface trafficking of GABABR and Girk channels is regulated
by phosphorylation-dependent mechanisms. For example,
phosphorylation of Ser-9 on Girk2 promotes internalization of
Girk2-containing channels, while dephosphorylation of Ser-783
on GABABR2 is associated with reduced surface expression of
the GABABR (Chung et al., 2009; Terunuma et al., 2010; Padgett
et al., 2012). Using phosphospecific antibodies, we next
evaluated whether the phosphorylation of Girk2(Ser-9) or
GABABR2(Ser-783) was altered by repeated cocaine in mPFC
tissue punches from saline- and cocaine-treated mice. While
no differences in the level of phosphorylated Girk2(Ser-9) were
detected between groups, repeated cocaine treatment corre-
lated with a significant reduction in the phosphorylation of
GABABR2(Ser-783) (Figure 6A).
As phosphatase PP2A can dephosphorylate GABABR2(pSer-
783) (Terunuma et al., 2010), we next evaluated the effect of
acute intracellular application of okadaic acid (OA; 100 nM) on
IBaclofen and excitability in layer 5/6 PrLC pyramidal neurons
(Figures 6B–6E). In saline-injected mice, there was no significant
effect of OA on IBaclofen or excitability, suggesting that tonic
phosphatase activity does not regulate GABABR-dependent
signaling or excitability in these neurons. In cocaine-treated
animals, however, OA normalized IBaclofen and excitability in layer
5/6 PrLC pyramidal neurons, suggesting that the redistribution of
GABABR and Girk2 from the surface membrane to intracellular
sites is linked to the dephosphorylation of GABABR2.
Girk Signaling in the mPFC and Behavioral Sensitization
Enhanced glutamatergic output from the prelimbic subregion of
the mPFC contributes to the development of cocaine-inducedbehavioral sensitization (Steketee and Kalivas, 2011). Data pre-
sented above suggest that the suppression of Girk signaling in
layer 5/6 PrLC pyramidal neurons contributes, at least in part,
to the cocaine-induced increase in excitability of these neurons.
To test whether the cocaine-induced suppression of Girk
signaling in the mPFC contributes to the development of behav-
ioral sensitization, we used a viral RNAi strategy to persistently
suppress Girk signaling in layer 5/6 of the dorsal aspect of the
mPFC. We infused bilaterally a mixture of lentiviruses harboring
shRNAs for Girk1 and Girk2 (Girk1/2-LV), or a GFP-non-target
control, into deep cortical layers of the dorsal mPFC of wild-
type mice (Figure 7A; Figure S5). Girk2 protein levels were signif-
icantly lower in mPFC micropunches from Girk1/2-LV mice as
compared to the control group (Figure 7B). Mice given intra-
mPFCGirk1/2-LV displayed normal motor activity during habitu-
ation (data not shown) and in response to saline injection but
showed elevated responses to the first three cocaine injections
(Figure 7C). Importantly, cocaine-induced activity levels for
Girk1/2-LV-treated mice did not differ between the first and fifth
injections and were indistinguishable from those exhibited by
control animals after their fifth cocaine injection. In contrast, con-
trol animals displayed a progressive increase in cocaine-induced
motor activity over the five injections. Collectively, these data
suggest that the persistent suppression of Girk signaling in layer
5/6 of the dorsal mPFC can presensitize mice to the motor-stim-
ulatory effect of cocaine.
DISCUSSION
Repeated cocaine exposure increases the excitability of layer
5/6 mPFC pyramidal neurons, making them more responsive
to cocaine and cocaine-associated cues (Sun and Rebec,Neuron 80, 159–170, October 2, 2013 ª2013 Elsevier Inc. 165
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Figure 7. Suppression of Girk Signaling in the mPFC and Behavioral
Sensitization
(A) Coronal brain sections (50 mm) showing eGFP labeling in the dorsal mPFC,
28 days after coinjection of two lentiviruses expressing Girk1- and Girk2-
specific shRNAs (Girk-LV; scale bar, 500 mm). The inset shows virus-infected
cells in themPFC (scale bar, 25 mm). fmi, forcepsminor of the corpus callosum.
(B) Top: representative subsections of immunoblots showing Girk2 (left) and
Girk1 (right) protein levels in tissue punches of themPFC from repeated saline-
and cocaine-treatedmice, 1 day after the final injection. Bottom: quantification
of Girk2 (t(17) = 3.1, p = 0.008), with normalization to the levels of b-actin (n = 9–
10/group).
(C) Distance traveled (m) after saline (sal) and five daily cocaine injections
(15 mg/kg, i.p.) in mice receiving intra-mPFC infusions of Girk1/2 lentivirus
(Girk-LV) or a nontarget GFP shRNA (eGFP-control; F(5,83) = 2.6, p < 0.05; n =
7–9/group) *p < 0.05 and **p < 0.01 versus eGFP-control; ##p < 0.01, injection 1
versus 5 (eGFP-control).
All data are presented as the mean ± SEM. See Figure S5 for time-dependent
expression of eGFP in virus-infused mice.
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Cocaine-Induced Adaptation in GABABR Signaling2006). One consequence of these adaptations is enhanced glu-
tamatergic output to the VTA and NAc, which is critical for the
development and expression of addictive behaviors such as
sensitization (Jayaram and Steketee, 2004; Steketee and Kali-
vas, 2011). GABABR-dependent signaling plays a fundamental
role in regulatingmPFC glutamatergic output to limbic structures
(Jayaram and Steketee, 2004; Harte and O’Connor, 2005), and
repeated cocaine exposure reduces GABABR-dependent inhib-
itory influences in the mPFC (Jayaram and Steketee, 2004; Ste-
ketee and Beyer, 2005). Here, we show that repeated cocaine
suppresses GABABR-Girk signaling in layer 5/6 PrLC pyramidal
neurons in a durable and specific manner, contributing to the
enhanced excitability of neurons implicated in the development
of addiction-related behavior.
Pharmacologic and genetic approaches revealed that most
(70%) of the direct inhibitory effect of GABABR activation in
layer 5/6 PrLC pyramidal neurons is attributable to Girk channel
activation. Importantly, repeated cocaine selectively suppressed
this dominant (Girk-dependent) component of IBaclofen. The Girk-
independent component of the GABABR-induced current was
suppressed by 8Br-cAMP, arguing that this conductance is
modulated via the Gi/o-dependent inhibition of adenylyl cyclase
activity and subsequent decline in intracellular cAMP. In light of166 Neuron 80, 159–170, October 2, 2013 ª2013 Elsevier Inc.the 8Br-cAMP sensitivity and recent studies (Deng et al., 2009;
Sandoz et al., 2012), the non-Girk component of IBaclofen may
be mediated by a two-pore domain Trek K+ channel. Modulation
of HCN channels may also play a role, however, as they are
found in layer 5/6 pyramidal neurons (Kase and Imoto, 2012).
DA input from the VTA influences the response of the mPFC to
reward (Wolf and Roth, 1987). We found that D1/5R antagonism
prevented the cocaine-induced suppression of GABABR-depen-
dent signaling and increased excitability of layer 5/6 PrLC pyra-
midal neurons. Repeated cocaine exposure has been shown to
upregulate cAMP signaling mPFC pyramidal neurons (Dong
et al., 2005) and reduce D2R-dependent inhibition in layer 5/6
mPFC pyramidal neurons (Nogueira et al., 2006), the latter of
which would further contribute to enhanced cAMP signaling.
Thus, the cocaine-induced, D1/5R-dependent suppression of
GABABR-Girk signaling in layer 5/6 PrLC pyramidal neurons
seen here may reflect enhanced activation of cAMP-dependent
signaling. Indeed, Szulczyk and colleagues demonstrated that a
Girk-like channel in mPFC pyramidal neurons was inhibited both
by D1R activation and cAMP (Witkowski et al., 2008, 2012).
While D1/5R activation in PrLC pyramidal neurons may trigger
the cocaine-induced suppression of GABABR-Girk signaling,
D1/5Rswere blocked globally in our study. Importantly, activation
of D5R signaling in the VTA was linked to the increase in excit-
atory transmission seen in VTA DA neurons triggered by cocaine
(Argilli et al., 2008). This form of plasticity occurs following a
single exposure to cocaine and facilitates a shift in the threshold
for induction of plasticity in downstream targets of the VTA,
including the mPFC (Mameli et al., 2009). Thus, if D1/5R antago-
nist pretreatment prevented excitatory adaptations in VTA DA
neurons in our study, it may also have blocked initiation of down-
stream adaptations in the mPFC, including the suppression of
GABABR-Girk signaling, that normally occur following repeated
cocaine exposure.
Local GABA interneurons and GABA-containing projection
neurons arising from the VTA are major sources of GABA in the
mPFC (Kawaguchi, 1993; Retaux et al., 1993; Carr and Sesack,
2000). Recently, Slesinger and colleagues demonstrated that
acute cocaine and methamphetamine exposure depressed
GABABR-Girk signaling in VTA GABA neurons in a D1/5R-depen-
dent manner (Padgett et al., 2012). Repeated cocaine exposure
also suppressed the influence of D2R on GABA interneurons of
the mPFC, leaving an unopposed D1R-mediated enhancement
of local GABA signaling (Kroener and Lavin, 2010). Together,
these observations provide reasonable explanations for the
elevated extracellular GABA levels seen in the mPFC of
cocaine-sensitized rats (Jayaram and Steketee, 2005, 2006)
and suggest the intriguing possibility that the cocaine-induced
suppression of GABABR-dependent signaling in layer 5/6 PrLC
pyramidal neurons reflects a desensitization of GABABR-Girk
signaling triggered by elevated GABA transmission.
Activation of the PrLC and its projections to the NAc core is
necessary for the development and expression of sensitization,
as well as initiating and reinstating cocaine-seeking behavior in
self-administering rats (Pierce et al., 1998; Tzschentke and
Schmidt, 2000; Kalivas and O’Brien, 2008). Activation of the
ILC and its projections to the shell region of the NAc is respon-
sible for inhibiting drug seeking during extinction training (Peters
Neuron
Cocaine-Induced Adaptation in GABABR Signalinget al., 2008). Akin to this functional dichotomy, we demonstrate
that while layer 5/6 pyramidal neurons in PrLC and ILC subre-
gions of the mPFC showed robust GABABR-Girk responses,
repeated cocaine exposure suppressed GABABR-Girk signaling
selectively in the PrLC. Moreover, persistent suppression of Girk
signaling, primarily targeting the dorsal aspect of the mPFC, was
sufficient to potentiate acute cocaine-inducedmotor activity and
prevent the augmentation of activity seen with repeated cocaine
dosing. These data support the contention that the cocaine-
induced suppression of Girk signaling contributes to increased
excitatory output from layer 5/6 PrLC pyramidal neurons that
are important for key aspects of addiction-related behavior,
including sensitization.
We reported previously that excitatory neurotransmission was
elevated in VTA DA neurons from Girk1–/– and Girk2–/– mice, ob-
servations that correlated with elevated levels of synaptic AMPA
receptors (Arora et al., 2010). Similar adaptations were observed
in NAc medium spiny neurons (Arora et al., 2010). AsGirk1 is not
expressed in VTA DA neurons, and neither Girk1 nor Girk2 are
abundantly expressed in the NAc (Karschin et al., 1996), these
adaptations are likely secondary to the loss of Girk signaling in
an afferent glutamatergic neuron population. Our work here
shows that Girk channels containing Girk1 and Girk2 temper
the excitability of layer 5/6 PrLC pyramidal neurons, a major
source of glutamate to the VTA and NAc. Thus, Girk signaling
in layer 5/6 PrLC pyramidal neurons may represent a barrier—
lowered by cocaine—to persistent adaptations in excitatory
neurotransmission in the VTA and/or NAc that promotes addic-
tion-related behaviors associated with drug seeking and relapse.
EXPERIMENTAL PROCEDURES
Animals
Animal use was approved by the Institutional Animal Care and Use Committee
at the University of Minnesota. Girk–/– mice have been used extensively to
characterize Girk contributions tometabotropic inhibitory signaling (e.g., Koyr-
akh et al., 2005). The Tg(Kcnj5-EGFP)49Gsat line was generated as part of the
GENSAT project and bred onsite. Male C57BL/6J mice were purchased from
The Jackson Laboratory for all studies involving cocaine.
Drugs
Cocaine hydrochloride, baclofen, sulpiride, SCH23390, guanfacine, quinpir-
ole, and barium chloride were purchased from Sigma. 8-Bromoadenosine
30,50-cyclic monophosphate (8Br-cAMP) and CGP54626 were purchased
from Tocris. Okadaic acid was purchased from MP Biomedicals.
Motor Activity
Activity studies were performed in open-field activity chambers as described
(Arora et al., 2011). Animals were acclimated to testing room, handling, and
chambers for 3 days prior to repeated cocaine or saline treatment. Subjects
received five injections of cocaine (15 mg/kg, intraperitoneally [i.p.]) or saline
over a 5–7 day period. For DA receptor antagonist experiments, mice were
pretreated with saline, SCH23390, or sulpiride 30 min prior to each saline or
cocaine injection.
Electrophysiology
Coronal slices (300 mm) containing the mPFC were prepared from wild-type
and Girk–/– mice (4–6 weeks), and repeated saline- or cocaine-treated
C57BL/6J mice (5–10 weeks), in an ice-cold solution containing 1.9 mM KCl,
1.2 mM Na2HPO4, 33 mM NaHCO3, 6 mM MgCl2, 0.5 mM CaCl2, 10 mM
glucose, 0.4 mM ascorbic acid, and 200 mM sucrose, bubbled with 95%
O2/5% CO2. Slices were transferred to prewarmed (32
C–35C) ACSF con-taining 125 mM NaCl, 2.5 mM KCl, 1.25 mM Na2HPO4, 25 mM NaHCO3,
4 mM MgCl2, 1 mM CaCl2, 10 mM glucose, and 0.4 mM ascorbic acid
(pH 7.3–7.4) and gradually acclimated to room temperature over the course
of R1 hr. Slices were transferred to a recording chamber and superfused
with oxygenated ACSF containing 125 mM NaCl, 2.5 mM KCl, 25 mM
NaHCO3, 1.3 mMMgCl2, 2.0 mMCaCl2, 10mM glucose, and 0.4mM ascorbic
acid (pH 7.3–7.4) at a flow rate of 2–2.5 ml/min. Bath and chamber tempera-
tures were maintained at 29C–30C. Borosilicate (3–5 MU) electrodes were
filled with 140 mM K-gluconate, 2 mM MgCl2, 1.1 mM EGTA, 5 mM HEPES,
2 mM Na2-ATP, 0.3 mM Na-GTP, and 5 mM phosphocreatine (pH 7.4). The
predicted EK for these conditionswas105mV. In some experiments, okadaic
acid (100 nM) was added to the pipette. Currents, resistances, and potentials
were measured using a Multiclamp 700A amplifier and pCLAMP v.9 software
(Molecular Devices) and stored on hard disk. All measured and command
potentials factored in a junction potential of 15 mV predicted using JPCalc
software (Molecular Devices).
Pyramidal neurons in layer 5/6 were identified based on a pyramidal-shaped
soma, a long apical dendrite extending toward superficial cortical layers, a
resting membrane potential %60 mV, lack of spontaneous activity, and an
apparent capacitance of R100 pF (Connors and Gutnick, 1990; Yang et al.,
1996; Kawaguchi and Kubota, 1997). For rheobase assessments, cells were
held in current-clamp mode and given 1 s current pulses beginning
at 60 pA and progressing to 200 pA in 20 pA increments. Agonist-induced
changes in holding current were measured at a holding potential (Vhold)
of 60 mV; holding current, input resistance, and series resistance values
were monitored during experiments by tracking responses to periodic
(0.2 Hz) voltage steps (5 mV, 800 ms). Only experiments with stable (<20%
variation) and low series resistances (<20 MU) were analyzed.
Retrograde Labeling
Male C57BL/6J mice (6–8 weeks) were anesthetized with ketamine
(100 mg/kg, i.p)/xylazine (10 mg/kg, i.p) and placed in a stereotaxic device
(David Kopf Instruments). A 5 ml Hamilton syringe was placed into the VTA
(from bregma: +3.08 mm AP, ± 0.5 mm ML; from ventral skull surface:
3.7 mm DV) or the NAc (from bregma: +1.1 mm AP, ± 1.0 mm ML; from
ventral skull surface: 3.8 mm DV) and remained in place for 2 min prior to
bilateral infusion (0.3–0.4 ml, 0.1 ml/min) of Retrobeads (LumaFlour) using an
UltraMicroPump with SYS-Micro4 controller (World Precision Instruments).
After a 10 min delay to reduce solution backflow along the infusion track, the
syringe was removed. Repeated cocaine treatment began after a suitable
period to allow for retrograde transport of Retrobeads from the VTA (18–
21 days) or NAc (10–15 days) to the mPFC. Retrobead injection sites were
determined by serial sectioning and staining with green Nissl (NeuroTrace
500/525, Molecular Probes). Mice with improper targeting or significant
bead contamination outside target areas were excluded from analysis.
qRT-PCR
mPFC punches (2 mm diameter, 2 mm thick) were taken from male C57BL/6J
mice (5–7 weeks), 1 day after the final cocaine or saline injection. Quantitative
analysis of GABABR1 and Girk2 mRNA levels was performed as described
(Arora et al., 2011).
Immunoblotting
mPFC punches (2 mm diameter, 2 mm thick) were sonicated in 1% SDS lysis
buffer containing a Halt phosphatase and protease inhibitor cocktail (Thermo
Fisher Scientific), heated at 85C for 10 min, and centrifuged at 4C for 20 min
at 16,000 3 g. Protein samples (40 mg) were separated by SDS-PAGE and
transferred to nitrocellulose membranes. Membranes were blocked in 5%
milk/Tris-buffered saline (TBS), incubated overnight at 4C with antibodies
against Girk2 (1:200; Alomone Labs), Girk2(pSer-9) (1:200; Chung et al.,
2009), GABABR1 (1:500; Kulik et al., 2003), GABABR2 (1:10; NeuroMab),
GABABR2(pSer-783) (1:200; PhosphoSolutions), or b-actin (1:10,000; Abcam),
diluted in 5% milk/TBS/0.1% Tween-20 or 1% milk/TBS/0.1% Tween-20.
Membranes were washed with TBS/0.1% Tween-20 or 1% milk/TBS/0.1%
Tween-20 and incubated with donkey anti-mouse (926-32212; 1:1,000–
5,000; LI-COR Biosciences) or anti-rabbit (926-68072; 1:5,000; LI-COR) sec-
ondary antibodies. Blots were developed using the Odyssey infrared imagingNeuron 80, 159–170, October 2, 2013 ª2013 Elsevier Inc. 167
Neuron
Cocaine-Induced Adaptation in GABABR Signalingsystem (LI-COR) and an integrated density of each band was measured using
ImageJ software (NIH).
Quantitative Immunoelectron Microscopy
The subcellular distribution of Girk2 and GABABR1 was measured using
pre-embedding immunoelectron microscopy and quantitative analysis
approaches, as described (Arora et al., 2011).
Lentiviral Suppression of Girk Signaling
pLKO.1-puro-CMV-eGFP-based shRNA constructs specific for Girk1
(TRCN0000069733, Sigma) and Girk2 (TRCN0000069814) were identified
based on their ability to suppress target expression in a heterologous system
(data not shown). These constructs, and a nontarget control, were used to
generate high-titer (>3 3 109 TU/ml) lentiviral stocks. Male C57BL/6J mice
(5–7 weeks) were anesthetized and secured in a stereotaxic device. Girk1
and Girk2 knockdown lentiviral stocks were mixed, loaded into a 5 ml Hamilton
syringe, and lowered into the mPFC. Two infusions (0.4 ml/infusion site;
0.2 ml/min) were made to ensure sufficient coverage in the mPFC
(from bregma: +1.9 mm AP, ± 0.3 mm ML; from ventral skull surface:
1.2/1.5 mm DV). After each infusion, the syringe was left in place for
5 min to reduce backflow. Mice began the repeated cocaine regimen 21–
24 days after viral infusion. Motor activity data were analyzed if bilateral
eGFP expression was detected in layer 5/6 of the dorsal portion of mPFC.
Data Analysis
Statistical analysis was performed using SigmaPlot (Systat Software). Motor
activity data were analyzed using one-way, two-way, and two-way
repeated-measures (RM) ANOVA, as appropriate. sEPSCs were analyzed
using Minianalysis software using a 20 pA detection threshold (Synaptosoft).
IBaclofen and current injection data were analyzed with Student’s t test or
one-way ANOVA, while current-spike relationships were analyzed with two-
way RM ANOVA. Immunoelectron microscopy data were analyzed using a
Mann-Whitney rank-sum test. Student Newman-Keuls post hoc test was
used for pairwise comparisons as appropriate. The threshold for statistical
significance was p < 0.05.
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